Ad Header



The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

Roche’s Alecensa bests Pfizer’s Xalkori in lung cancer trial

Roche Holding AG’s Alecensa halted the spread of lung cancer for a median of 15 months longer than treatment with rival Pfizer Inc.’s Xalkori with fewer side effects, according to trial results.

Read More »

Pfizer drug delays lung cancer growth longer than Astra’s Iressa: study

A targeted drug being developed by Pfizer Inc. held advanced lung cancer in check longer than AstraZeneca’s Iressa in newly diagnosed patients, but with a higher rate of side effects, according to data.

Read More »

Merck KGaA, F-star Alpha Strike Deal

Merck KGaA struck a deal worth up to €1 billion to acquire five bispecific immuno-oncology antibodies from F-star Alpha.

Read More »

Investors Sigh With Relief as bluebird bio, Celgene’s CAR-T Candidate Keeps Multiple Myeloma Patients Relapse Free

Although a lot of attention went to unexpected data by China’s Nanjing Legend Biotech, bluebird bio and Celgene had CAR-T data of their own to brag about.

Read More »

Loxo Oncology Seeks FDA Approval After Breakthrough Drug Larotrectinib Helped Almost Everyone Who Took It

Shares of Loxo Oncology rocketed up more than 48 percent after the company unveiled data from three trials that showed treatment with larotrectinib helped nearly three-quarters of patients battling a variety of cancers.

Read More »

Lynparza slows advanced breast cancer progression

Women with advanced breast cancer who carry specific genetic mutations experienced double the response rate and delayed disease progression when treated with AstraZeneca’s Lynparza versus standard chemotherapy, according to a late-stage trial.

Read More »

Pfizer defeats appeals over Zoloft birth defects

Pfizer defeated an effort to revive 300+ lawsuits alleging that its antidepressant Zoloft causes cardiac birth defects in children when taken by women during early pregnancy.

Read More »

U.S. state, local government lawsuits over opioids face uphill battle

A growing number of U.S. states, counties and cities are filing lawsuits accusing drug companies of deceptively marketing opioid painkillers to downplay their addictiveness, but some lawyers say the industry’s highly regulated nature could pose a hurdle to their success.

Read More »

Stock Tanks as Endocyte Cuts 40% of Workforce, Slashes 2 Clinical Programs

Endocyte announced the cutting of 40 percent of its workforce as the company recalibrates two clinical programs, EC1169 and EC1456.

Read More »

Elated Bristol-Myers Squibb, Seattle Genetics Rewrite Agreement to Push Promising Drug Combo Into Phase III

Six months after touting positive data from a Phase I/II combination study of Opdivo and Adcetris in patients with relapsed or refractory classical Hodgkin lymphoma at the American Society of Hematology, Bristol-Myers Squibb and Seattle Genetics are plowing forward into a Phase III trial.

Read More »

Ad Right Top


Extensive pharmaceutical business and marketing intelligence. For back issues, please contact

August 2019 Focus: AI, AR/VR, Top 200 Medicines, Lions Health Takeaways, and more!


Ad Right Bottom